Ansell named chair of nbca’s medical and scientific advisory board

Ansell named chair of nbca’s medical and scientific advisory board

Tarrytown, NY.  June 11, 2008.  The National Blood Clot Alliance (NBCA) announced that Jack E. Ansell, MD has been selected to chair NBCA’s prestigious Medical and Scientific Advisory Board (MASAB) effective September 1, 2008.  Dr. Ansell is the Chairman of the Department of Medicine at Lenox Hill Hospital in New York City. Before joining Lenox Hill Hospital, Dr. Ansell was Professor of Medicine at Boston University School of Medicine and Vice Chairman for Clinical Affairs of the Department of Medicine.

NBCA President, Randy Fenninger, stated that “we are fortunate to have Dr. Ansell, an internationally recognized expert in the field of hemostasis and thrombosis in this leadership position.”  Dr. Ansell is the author of more than 200 publications including, original research, reviews, editorials, chapters, and books.

Dr. Ansell’s main areas of research focus on the clinical problems of thrombosis, thrombotic disorders, and anti-thrombotic therapy.  “Dr. Ansell is at the cutting edge of new methods of delivering and monitoring anti-coagulants, particularly in the management of oral anti-coagulant therapy and is involved in the clinical study of new oral anti-coagulants,” noted Dr. Stephan Moll, the current Chair of MASAB.

Alan P. Brownstein, NBCA Executive Director, states that “Dr. Ansell is the founder and immediate past President of the Anticoagulation Forum (www.acforum.org), a network of 1500 anti-coagulation clinics.”  Dr. Ansell and the Anticoagulation Forum have always been “friends of NBCA” as NBCA has frequently contributed to the meetings of the Anticoagulation Forum and its newsletter.

Dr. Ansell stated that, “I am looking forward to chairing MASAB to help patients and medical and scientific leaders speak with a unified voice to increase the awareness of the enormous risks of thrombosis or clotting, most of which can be avoided.”

A graduate of the University of Virginia School of Medicine, Dr. Ansell completed his medical residency at Tufts New England Medical Center in Boston.  He then completed a fellowship in Hematology at BU and in Hematology/Hemostasis at Boston’s VA Hospital.

Dr. Ansell will succeed NBCA’s first MASAB Chair, Stephan Moll, MD, who will now be serving as NBCA’s First Medical Director.

The National Blood Clot Alliance (NBCA) is a nationwide community-based patient advocacy organization.  NBCA’s mission is to prevent, diagnose, and treat thrombosis and thrombophilia through research, education, support and advocacy.  NBCA’s patient leadership is supported by national medical and scientific leaders (MASAB) to advance NBCA’s mission. With support from the Centers for Disease Control (CDC), NBCA is at the beginning of a two year project directed at educating consumers, patients and healthcare professionals to prevent clotting related morbidity and mortality.  Annually, there are 900,000 venous thromboembolisms and 300,000 deaths in the US, many of which are preventable.